Wockhardt

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Wockhardt sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).

27 total trials none currently recruiting 26 completed early-phase tilt top decile by trial count

Wockhardt: 27 sponsored US clinical trials, none currently recruiting.

Wockhardt sponsors 27 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 26 completed. 2 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects (HS), with 1 trials.

Top-decile sponsor footprint

Wockhardt ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 81/100

26 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (96.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

27 total, page 1 of 1

COMPLETED Phase 1

A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.

NCT06806995

COMPLETED Phase 3

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT04979806

COMPLETED Phase 1

Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin

NCT03981887

COMPLETED Phase 1

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

NCT03622008

COMPLETED Phase 1

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

NCT07247942

COMPLETED Phase 1

Plasma and Intrapulmonary Concentrations Study of WCK 5222

NCT03630094

COMPLETED Phase 1

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT03554304

COMPLETED Phase 2

Phase II Study of Oral Nafithromycin in CABP

NCT02903836

COMPLETED Phase 1

To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment

NCT02942810

COMPLETED Phase 1

A Phase 1 Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects

NCT02770404

COMPLETED Phase 1

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

NCT02709382

COMPLETED Phase 1

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

NCT02707107

COMPLETED Phase 1

MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults

NCT02674347

COMPLETED Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime

NCT02532140

COMPLETED Phase 1

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects

NCT02453529

COMPLETED Phase 1

Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects

NCT02253342

COMPLETED Phase 1

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

NCT02244827

COMPLETED Phase 1

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

NCT02217930

COMPLETED Phase 1

Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

NCT01875939

COMPLETED Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

NCT05640531

COMPLETED Phase 1

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

NCT01357603

TERMINATED Phase 3

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

NCT01308437

COMPLETED Phase 1

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

NCT01358435

COMPLETED Phase 1

Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects

NCT00772265

COMPLETED Phase 1

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

NCT00752180

COMPLETED Phase 1

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.

NCT00719108

COMPLETED Phase 1

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.

NCT00596063

How the Wockhardt early-phase archive is shaped

27 indexed studies, none listed as recruiting (0% open); 26 completed (96%).

Phase mix: 2 late (III/IV) vs 25 early (I/II) (early-phase heavy).

Top condition: Healthy Subjects (HS) (1 trial), 7 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Wockhardt: archived-pipeline peers nationwide

Peers matched on 27 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Wockhardt sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030 0%5%10%15%20% Total trials Recruiting share WockhardtAkron Children's HospitalArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)AVEO PharmaceuticalsDompé Farmaceutici S.p.A10xBio22nd Century Group23andMe3-C Institute for Social Development
Wockhardt sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wockhardt sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 27 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Wockhardt page

27 registered trials is a research-attention snapshot, not an endorsement of Wockhardt or any single study.

  • None of Wockhardt's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Subjects (HS) is the condition Wockhardt studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects (HS) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wockhardt pipeline card: 27 registered trials from official public datasets.Report a data error.